After Brazil Onto China? Amgen Unveils Emerging Market Strategy
This article was originally published in PharmAsia News
The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say
You may also be interested in...
Amgen is expected to announce a JV in Japan soon, the company said during a business strategy meeting last week. It expects China, Japan and other emerging markets to bring in roughly $1 billion more in revenue by 2015.
After tackling Brazil and Turkey, Amgen looks to ramp up in Japan and China, while BMS talks up its first-to-market opportunity for an all-oral hepatitis C regimen in Japan.
PharmAsia News takes a closer look at presentations by Amgen, Gilead, Merck, Sanofi and Stryker